Investigational Site Number : 3760001
Haifa 3109601
3 studies enrolling now · 11 studies all time
What they study most
Asthma, Chronic Inflammatory Demyelinating Polyneuropathy, Dermatitis Atopic, Glycogen Storage Disease Type II, Multiple Sclerosis, Non-small Cell Lung Cancer Metastatic, Polymyalgia Rheumatica, Pompe Disease, Type 1 Diabetes Mellitus, Type 2 Diabetes Mellitus
Studies at this site
- A Study to Test the Efficacy and Safety of Riliprubart Against the Usual Treatment of Intravenous Immunoglobulin (IVIg) in People With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) — Recruiting now
- Pompe Disease Registry Protocol — Recruiting now
- A Study to Evaluate the Efficacy and Safety of Subcutaneous Amlitelimab Monotherapy Compared With Placebo in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis — Completed
- Efficacy and Safety Studies of Frexalimab (SAR441344) in Adults With Relapsing Forms of Multiple Sclerosis — Running, not enrolling
- A Study to Evaluate the Treatment Response and Safety of Two Dose Regimens of Subcutaneous Amlitelimab Compared With Treatment Withdrawal in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis — Running, not enrolling
- Long-term Safety and Efficacy Evaluation of Lunsekimig (SAR443765) in Adult Participants With Asthma — Enrolling by invitation
- SAR408701 Versus Docetaxel in Previously Treated, Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Positive Metastatic Non-squamous Non-small-cell Lung Cancer Patients — Stopped early
- Dose Ranging Study of Lunsekimig Compared With Placebo-control in Adult Participants With Moderate-to-severe Asthma — Completed
- Evaluation of the Efficacy and Safety of Sarilumab in Patients With Polymyalgia Rheumatica — Stopped early
- Efficacy and Safety of the Insulin Glargine/Lixisenatide Fixed Ratio Combination (FRC) Versus GLP-1 Receptor Agonist in Patients With Type 2 Diabetes, With a FRC Extension Period — Completed
- Comparison of the Safety and Efficacy of HOE901-U300 With Lantus in Children and Adolescents With Type 1 Diabetes Mellitus — Completed